Spectrophotometeric Determination of Dexrabeprazole Sodium and Domperidone Maleate in Bulk and Capsule Dosage Form by First Order Derivative Spectroscopy

In the present work, a simple, economical, precise and accurate method for determination of Dexrabeprazole sodium (DEX) and Domperidone maleate (DOM) in combined dosage form has been developed. Dexrabeprazole sodium is a proton pump inhibitor and Domperidone maleate is an antiemetic drug. In combination the drugs are commercially available as capsule dosage form for oral administration. Literature survey reveals one spectrophotometric method and one RP-HPLC method has been reported for DEX in combined dosage form. No analytical method is available for estimation of DEX in single dosage form. Domperidone alone or in combination with other drugs is reported to be estimated by spectrophotometry, HPLC, LC, LC-MS, and HPTLC method. A first order derivative spectroscopic method has been developed for determination of Dexrabeprazole sodium (DEX) and Domperidone maleate (DOM) in the capsule dosage form in which derivative amplitudes were measured at selected wavelengths. The wavelengths at 253 nm and 266 nm in the first order derivative spectra were selected to determine DOM and DEX, respectively. Beer's law is obeyed in the concentration range of 2–36 μg/ml for DEX and 6–36 μg/ml and for DOM. The results of analysis have been validated statistically, which confirm the accuracy and reproducibility of the method. Recovery was found in the range of 99.94 – 102.5% for DEX and 99.88 – 100.08% for DOM. The proposed method was applied successfully to determine uniformity of contents in commercial capsule formulations.